Berkeley Advanced Biomaterials Granted FDA Approval
to Market Cem-Ostetic™ Injectable Putty in U.S.

01/09/2003 Berkeley, California. The U.S. Food and Drug Administration has approved an innovative bone void filler from Berkeley Advanced Biomaterials, Cem-Ostetic™ Putty.

"FDA approval of Cem-Ostetic™ marks our entry into the U.S. market," according to Berkeley Advanced Biomaterials co-founder and CEO Dr. François Génin. "We began sales of our Ostetic product line overseas in 2002. We are very pleased that Cem-Ostetic™ injectable putty is our first domestically approved bone graft product as we establish our U.S. distribution network."

Cem-Ostetic™ is a buffered synthetic bone putty that contains calcium-based biocompatible salts that have been used for decades in orthopedic surgery. The putty is created simply by combining pre-measured doses of water and powder. The putty can be injected or formed into an implant and hardens in fewer than 5 minutes. Cem-Ostetic™ has excellent resorbtion properties and is very cost-effective for bone fill applications.

For more information on the Ostetic product line and on how to purchase Ostetic products, please visit the company's web site: http://www.ostetic.com.

About Berkeley Advanced Biomaterials:
Formed in 1996 to develop biomaterials for orthopedic applications, BAB introduced its Ostetic line of bone filler materials in 2002. The company continues to work with academic and corporate laboratories to develop novel biomaterials. BAB is a privately held company with headquarters in Berkeley, California. For more information, visit the company's website: http://www.ostetic.com.